<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503930</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-15-NG-261-CTIL</org_study_id>
    <nct_id>NCT02503930</nct_id>
  </id_info>
  <brief_title>The Effect of tDCS on a Motor-cognitive Dual-task Performance of Parkinson's Patients</brief_title>
  <official_title>The Effect of Transcranial Direct Cortical Stimulation (tDCS) on a Motor-cognitive Dual-task Performance of Parkinson's Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tel Aviv University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The concurrent performance of two tasks, i.e., dual tasking (DT), is a common and ubiquitous
      every day phenomena. For example, people frequently walk while talking on a cellphone or
      drive while talking to a passenger. Often, the performance of one or more of these
      simultaneously performed tasks may deteriorate when another task is carried out at the same
      time, even in healthy young adults. This reduction in performance is referred to as the DT
      deficit or DT cost and is typically much higher in patients with Parkinson's disease (PD)
      than in young adults or age-matched controls. In PD, this DT cost impairs the gait pattern,
      as manifested, for example, in increased gait variability, exacerbating instability and fall
      risk.

      In the proposed study, would be evaluated the effects of tDCS on dual tasking performance
      following tDCS.

      The researchers expect that stimulation of the Pre Frontal Cortex (PFC) (using tDCS) will
      increase DT performance and prefrontal activation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      tDCS intervention: Noninvasive tDCS will be delivered by study personnel uninvolved with any
      other study procedures. In the study will be used a battery-driven electrical stimulator.
      Stimulation and sham condition will be performed based on previous studies. Briefly, the
      anode will be placed over the PFC and the cathode over the right supraorbital region. The
      real tDCS condition will consist of 20 min of continuous stimulation at target intensity of
      1.5 mA. This amount of stimulation is safe for healthy young and older adults and has been
      shown to induce acute beneficial changes in cortical excitability and cognitive functions.
      For the sham condition, an inactive stimulation protocol would be followed, as compared with
      an 'off-target' active protocol, in order to minimize participant risk. After each session,
      subjects will complete a side effects questionnaire. The efficacy of tDCS blinding will also
      be assessed after the final session, by asking each subject to judge whether they received
      real or sham tDCS, as well as their certainty of this judgment. Pre- and post-tDCS
      assessments will include:

      fMRI: All of the MR images will be acquired on a 3.0 T scanner using an 8-channel head coil.
      T1-weighted brain volume (BRAVO) acquisitions will evaluate gray matter (GM) volume and
      thickness, markers of brain atrophy. This sequence will measure the ratio of GM within the
      PFC to overall GM, which will then be used to quantify the level of activation within the
      PFC. T2* echo planner imaging acquisition will be used for all the DT paradigms including
      intrinsic functional connectivity. Intrinsic connectivity will be examined while subjects are
      not engaged in any particular task and are requested to lie still with their eyes open (i.e.,
      resting state). To examine task related changes versus more generalized patterns of DT
      activations, the type of the cognitive task or the nature of the motor task will be different
      in each task. The researchers will specifically examine the contribution of a secondary task
      involving working memory (arithmetic processing vs. attention), conflict monitoring, and
      motor planning on DT related activations.

      fNIRS : fNIRS will be used to investigate the role of the frontal lobe in DT walking and how
      it is affected by tDCS [Mirelman et al. 2014]. The fNIRS system (Oxymon MKIII; Artinis
      Medical Systems) consists of flexible circuit board that carries the near-infrared light
      sources and detectors. The fNIRS sources and detectors pairs will be placed over the left
      (Fp1) and right (Fp2) frontal cortex regions of the forehead, as previously reported.

      Gait assessment: Gait parameters will include both spatial and temporal parameters obtained
      using body fixed wearable sensors (accelerometers and gyroscopes) [Weiss et al. 2015;Ben et
      al. 2015]. Parameters will include (but are not limited to) gait speed, stride length and
      stride time as well as rhythmicity measures such as stride to stride variability and gait
      regularity.

      The UPDRS, fall history and fear of falling will also be assessed (e.g., Falls Efficacy Scale
      International, FES-I) to further characterize the cohort and explore possible confounds.

      Cognitive assessment: A detailed computerized cognitive battery that has been used
      extensively at TASMC in PD and other cohorts [Dwolatzky et al. 2003;Hausdorff et al.
      2006;Springer et al. 2006;Yogev et al. 2005;Aarsland et al. 2003] will quantify several
      cognitive domains including working memory, executive function, verbal function, problem
      solving, a global cognitive score, and attention.

      Sample size: Based on the effects of tDCS on DT walking outcomes in other cohorts [Leite et
      al. 2014;Zhou et al. 2014], the research group consider a conservative change of 15% in HbO2
      levels after tDCS, as compared to sham, 18 subjects per group will provide &gt;80% power. In
      order to allow for potential inter-subject variability and to address secondary questions
      (e.g., effect of disease severity), would be to assess 30 participants in each group.

      Data collection:

      A research assistant will assist participants filling in the electronic questionnaires and
      will conduct the non electronic ones (these would be later transcribed to excel sheets by
      research assistants).

      A post-doc fellow and a PhD student will run the MRI scans and the tDCS sessions together
      with one-two research assistants. The participants will receive a reminder (by phone and or
      email) one day prior to each session. Participation will be monitored by the research
      assistants.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in frequency and severity of the freezing of gait phenomenon</measure>
    <time_frame>One week post intervention</time_frame>
    <description>The new version of the Freezing of Gait questionnaire will be used to quantify the frequency and severity of this symptom. The score will be compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fMRI scans - changes in gray matter (GM) volume</measure>
    <time_frame>One week post intervention</time_frame>
    <description>All of the MR images will evaluate gray matter (GM) volume, markers of brain atrophy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fNIRS related frontal lobe activation - changes in tissue oxygenation</measure>
    <time_frame>One week post intervention</time_frame>
    <description>fNIRS will be used to investigate the role of the frontal lobe in DT walking and how it is affected by tDCS.The fNIR system provides with real-time monitoring of tissue oxygenation in the brain as subjects take different tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cognitive performance</measure>
    <time_frame>One week post intervention</time_frame>
    <description>The NeuroTrax software uses tests of cognitive performance that measure similar cognitive functions to traditional paper-based tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immediate change in gait speed</measure>
    <time_frame>One week post intervention</time_frame>
    <description>Gait speed will be assessed under usual and dual task conditions and while negotiating physical obstacles, using a sensorized 7 meter carpet (PKMAS) and wearable body fixed sensors. These measures will be compared to baseline performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immediate change in gait variability</measure>
    <time_frame>One week post intervention</time_frame>
    <description>Gait variability will be assessed under usual and dual task conditions and while negotiating physical obstacles, using a sensorized 7 meter carpet (PKMAS) and wearable body fixed sensors. These measures will be compared to baseline performance.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Active tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The Sham tDCS - an inactive stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active tDCS</intervention_name>
    <description>In this group subjects will receive 20 min of treatment.</description>
    <arm_group_label>Active tDCS</arm_group_label>
    <other_name>Transcranial Direct Current Stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham tDCS</intervention_name>
    <description>In this group subjects will receive 20 min of sham stimulation.</description>
    <arm_group_label>Sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of idiopathic PD (defined by the UK Brain Bank criteria)

          2. Hoehn and Yahr score between 1.5-3

          3. Taking anti-parkinsonian medications.

        Exclusion Criteria:

          1. Mini Mental State Exam (MMSE) score =&lt; 24

          2. Brain surgery in the past including implanted DBS

          3. Major depression (DSM-IV Criteria)

          4. Cerebral Infarction with Residual Deficits Diagnosis

          5. Neurological diseases (except from PD)

          6. Orthopaedic or cardiovascular diseases that may affect walking and cognitive
             abilities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nir Giladi, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv Sourasky medical Center, Tel Aviv, Israel. Phone: 972-3-6974790</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anat Mirelman, PhD</last_name>
    <phone>972-3-6974958</phone>
    <email>anatmi@tlvmc.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeffery M Hausdorff, PhD</last_name>
    <phone>972-3-6974958</phone>
    <email>jhausdor@tlvmc.gov.il</email>
  </overall_contact_backup>
  <reference>
    <citation>Zhou J, Hao Y, Wang Y, Jor'dan A, Pascual-Leone A, Zhang J, Fang J, Manor B. Transcranial direct current stimulation reduces the cost of performing a cognitive task on gait and postural control. Eur J Neurosci. 2014 Apr;39(8):1343-8. doi: 10.1111/ejn.12492. Epub 2014 Jan 20.</citation>
    <PMID>24443958</PMID>
  </reference>
  <results_reference>
    <citation>Leite J, Gon√ßalves OF, Carvalho S. Facilitative effects of bi-hemispheric tDCS in cognitive deficits of Parkinson disease patients. Med Hypotheses. 2014 Feb;82(2):138-40. doi: 10.1016/j.mehy.2013.11.021. Epub 2013 Dec 1.</citation>
    <PMID>24332532</PMID>
  </results_reference>
  <results_reference>
    <citation>Springer S, Giladi N, Peretz C, Yogev G, Simon ES, Hausdorff JM. Dual-tasking effects on gait variability: the role of aging, falls, and executive function. Mov Disord. 2006 Jul;21(7):950-7.</citation>
    <PMID>16541455</PMID>
  </results_reference>
  <results_reference>
    <citation>Weiss A, Herman T, Giladi N, Hausdorff JM. New evidence for gait abnormalities among Parkinson's disease patients who suffer from freezing of gait: insights using a body-fixed sensor worn for 3 days. J Neural Transm (Vienna). 2015 Mar;122(3):403-10. doi: 10.1007/s00702-014-1279-y. Epub 2014 Jul 29.</citation>
    <PMID>25069586</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 9, 2015</study_first_submitted>
  <study_first_submitted_qc>July 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2015</study_first_posted>
  <last_update_submitted>July 19, 2015</last_update_submitted>
  <last_update_submitted_qc>July 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>michal roll</investigator_full_name>
    <investigator_title>Director of Research and Development</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

